A threshold level of intratumor CD8+ T-cell PD1 expression dictates therapeutic response to anti-PD1

Cancer Research

Volumn 75, Issue 18, 2015, Pages 3800-3811

  Ngiow, Shin Foong ^a,b   Young, Arabella ^a,b   Jacquelot, Nicolas ^c,d,e,f   Yamazaki, Takahiro ^c,d,e,f   Enot, David ^c,d,e,f   Zitvogel, Laurence ^c,d,e,f   Smyth, Mark J ^a,b  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c University Paris XI   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

^f Center of Clinical Investigations in Biotherapies of Cancer (CICBT)   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; CD274 PROTEIN, MOUSE; PDCD1 PROTEIN, MOUSE; PROGRAMMED DEATH 1 LIGAND 1; TUMOR PROTEIN;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RESISTANCE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG SENSITIVITY; IMMUNOCOMPETENT CELL; LYMPHOCYTE FUNCTION; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TREATMENT RESPONSE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ADENOCARCINOMA; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BONE MARROW CELL; C57BL MOUSE; COLONIC NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MAMMARY NEOPLASMS, EXPERIMENTAL; METABOLISM; PASSIVE IMMUNIZATION; PHYSIOLOGY; TRANSGENIC MOUSE; TUMOR ASSOCIATED LEUKOCYTE;

ADAPTIVE IMMUNITY; ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; CD8-POSITIVE T-LYMPHOCYTES; COLONIC NEOPLASMS; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNIZATION, PASSIVE; LYMPHOCYTES, TUMOR-INFILTRATING; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; MYELOID CELLS; NEOPLASM PROTEINS; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES, REGULATORY; TUMOR MICROENVIRONMENT;

EID: 84942919454     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-1082     Document Type: Article

References (33)

1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survivalwith ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
3. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermottDF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in Cancer. N Engl J Med 2012;366:2443-54.
4. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015;372:311-19.
5. Hamid O, Robert C, Daud A, Hodi FS, Hwu W-J, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134-44.
6. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320-30.
7. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014;515:558-62.
8. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012;4:127ra37.
9. Atefi M, Avramis E, Lassen A, Wong DJ, Robert L, Foulad D, et al. Effects of MAPK and PI3K pathways on PD-L1 expression inmelanoma. Clin Cancer Res 2014;20:3446-57.
10. Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007;13:84-8.
11. Xu C, Fillmore CM, Koyama S, Wu H, Zhao Y, Chen Z, et al. Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell 2014;25:590-604.
12. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor E J M, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568-71.
13. Yao S, Zhu Y, Chen L. Advances in targeting cell surface signalling molecules for immune modulation. Nat Rev Drug Discov 2013;12:130-46.
14. Giorgini A, Brown HJ, Lock HR, Nimmerjahn F, Ravetch JV, Verbeek JS, et al. FcgRIII and FcgRIV are indispensable for acute glomerular inflammation induced by switch variant monoclonal antibodies. J Immunol 2008;181:8745-52.
15. Hazenbos WL, Gessner JE, Hofhuis FM, Kuipers H, Meyer D, Heijnen IA, et al. Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc gamma RIII (CD16) deficient mice. Immunity 1996;5:181-8.
16. Nimmerjahn F, Lux A, Albert H, Woigk M, Lehmann C, Dudziak D, et al. FcgRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo. Proc Natl Acad Sci 2010;107:19396-401.
17. Takai T, LiM, Sylvestre D, Clynes R, Ravetch JV. FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell 1994;76:519-29.
18. Kim JM, Rasmussen JP, Rudensky AY. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol 2007;8:191-97.
19. Ngiow SF, von Scheidt B, Akiba H, Yagita H, Teng M W L, Smyth MJ. Anti-TIM3 antibody promotes T Cell IFN-g-mediated antitumor immunity and suppresses established tumors. Cancer Res 2011;71:3540-51.
20. Verbrugge I, Hagekyriakou J, Sharp LL, Galli M, West A, McLaughlin NM, et al. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res 2012;72:3163-74.
21. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci 2010;107:4275-80.
22. Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-Cell rejection function in tumors. Cancer Res 2013;73:3591-603.
23. Sakuishi K, Ngiow SF, Sullivan JM, TengMWL, Kuchroo VK, SmythMJ, et al. TIM3+FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. Onco Immunol 2013;2:e23849.
24. Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T, Srinivasan M, et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 2013;1:32-42.
25. Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells codefines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 2013;210:1695-710.
26. Bulliard Y, Jolicoeur R, Windman M, Rue SM, Ettenberg S, Knee DA, et al. Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med 2013;210:1685-93.
27. Penaloza-MacMaster P, Kamphorst AO, Wieland A, Araki K, Iyer SS, West EE, et al. Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection. J Exp Med 2014;211:1905-18.
28. KaoC, OestreichKJ, Paley MA, Crawford A, Angelosanto JM, Ali M-AA, et al. Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection. Nat Immunol 2011;12:663-71.
29. Herbst RS, Soria J-C, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563-67.
30. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-33.
31. Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015;520:373-7.
32. Voron T, Colussi O, Marcheteau E, Pernot S, Nizard M, Pointet A-L, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med 2015;212:139-48.
33. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124-28.